11/18
01:40 pm
stro
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
11/18
08:09 am
stro
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/13
04:44 pm
stro
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
High
Report
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
11/13
04:30 pm
stro
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
High
Report
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
11/4
04:05 pm
stro
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Medium
Report
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
11/1
08:00 am
stro
Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Medium
Report
Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
10/20
10:52 am
stro
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago [Yahoo! Finance]
Low
Report
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago [Yahoo! Finance]
10/15
01:20 pm
stro
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRa Remain Viable? [Seeking Alpha]
Low
Report
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRa Remain Viable? [Seeking Alpha]
10/11
03:01 pm
stro
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock.
Low
Report
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock.
10/11
08:41 am
stro
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/10
04:05 pm
stro
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
High
Report
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
9/20
04:08 pm
stro
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
9/20
04:01 pm
stro
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/16
10:55 am
stro
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Medium
Report
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
9/16
08:03 am
stro
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
High
Report
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
9/14
03:14 am
stro
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 [Yahoo! Finance]
High
Report
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 [Yahoo! Finance]
9/14
03:00 am
stro
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
High
Report
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
9/11
08:00 am
stro
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Low
Report
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
8/26
01:02 pm
stro
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why [Yahoo! Finance]
Low
Report
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why [Yahoo! Finance]